Drugs / ARX201
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00778518 Comparator | Jul 2008 → Oct 2009 | pituitary deficiency | Ambrx, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ARX201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00778518 ↗ |
| Known as | PEG-ahGH | “The primary objective of this study is to evaluate the safety, tolerability and pharmacodynamic response of three different ARX201 doses (PEG-ahGH) when administered repeatedly...” NCT00778518 ↗ |